Cargando…

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications

Activation of JAK-STAT signaling is one of the hallmarks of myelofibrosis, a myeloproliferative neoplasm that leads to inflammation, progressive bone marrow failure, and a risk of leukemic transformation. Around 90% of patients with myelofibrosis have a mutation in JAK2, MPL, or CALR: so-called ‘dri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ross, David M., Babon, Jeffrey J., Tvorogov, Denis, Thomas, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094080/ https://www.ncbi.nlm.nih.gov/pubmed/33472356 http://dx.doi.org/10.3324/haematol.2020.262691

Ejemplares similares

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Management of myelofibrosis after ruxolitinib failure
por: Harrison, Claire N, et al.
Publicado: (2020)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

Definition and management of ruxolitinib treatment failure in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2014)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis
por: Hirano, Anna, et al.
Publicado: (2017)

Ruxolitinib therapy and telomere length in myelofibrosis
por: Caocci, G, et al.
Publicado: (2016)

A Case of Hepatitis E Persistence in a Patient With Myelofibrosis Under Ruxolitinib
por: Ribeiro da Cunha, Maria, et al.
Publicado: (2021)

Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis
por: Hasan, Kawa M., et al.
Publicado: (2022)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
por: Harrington, P., et al.
Publicado: (2022)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
por: Stoeva, Vera, et al.
Publicado: (2023)

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2015)

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
por: Mesa, Ruben A, et al.
Publicado: (2013)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
por: Claudiani, Simone, et al.
Publicado: (2021)

Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
por: Li, Yujin, et al.
Publicado: (2020)

Ruxolitinib therapy for myelofibrosis in Austria: Consensus on therapy management
por: Krauth, Maria-Theresa, et al.
Publicado: (2018)

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
por: Tvorogov, Denis, et al.
Publicado: (2018)

Real-life ruxolitinib experience in intermediate-risk myelofibrosis
por: Arikan, Fatma, et al.
Publicado: (2021)

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
por: Abidi, Maheen Z., et al.
Publicado: (2016)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

Marked Hyperbilirubinemia Associated with Primary Myelofibrosis Responsive to Ruxolitinib
por: Sandhu, Sunny, et al.
Publicado: (2022)

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
por: Harrison, Claire N., et al.
Publicado: (2020)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
por: Verstovsek, Srdan, et al.
Publicado: (2013)

EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis
por: Prem, Shruti, et al.
Publicado: (2019)

P1018: TREND OF CIRCULATING CD34+ CELLS IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB
por: Cattaneo, D., et al.
Publicado: (2022)

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
por: Harrison, Claire, et al.
Publicado: (2022)

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
por: Harrison, Claire N., et al.
Publicado: (2016)

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
por: Pugliese, Novella, et al.
Publicado: (2019)

Ruxolitinib changes the natural course of myelofibrosis and its transplant outcome
por: Jung, Chul Won
Publicado: (2013)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
por: Palandri, F., et al.
Publicado: (2022)

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
por: Verstovsek, Srdan, et al.
Publicado: (2017)

Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib—A Real-Life Longitudinal Study
por: Stoeva, Vera, et al.
Publicado: (2023)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
por: Dold, Leona, et al.
Publicado: (2021)

Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms
por: Bjørn, Mads Emil, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pghfq9ac12o6aqmsk9o178pp27